Meet Our Management Team

Our core management team combines the relevant HIV/AIDS and oncology development experience: Pharmaceutical industry, biotech and academia. We opt for outsourcing manufacturing and regulatory (based on past experience of other biotech companies developing advanced therapies).

Dr. Mark Dybul

Executive Vice Chairman


Dr. Dybul has served as a Professor in the Department of Medicine at Georgetown University Medical Center, and the Faculty Co-Director of the Center for Global Health and Quality since June of 2017. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher, and administrator, most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. Dr. Dybul was one of the founding architects in the formation of the U.S. President’s Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical officer, Assistant, Deputy and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. Earlier in his career, after graduating from Georgetown Medical School in Washington D.C., Dr. Dybul joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. Dr. Dybul has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University. Dr. Dybul is a member of the national academy of medicine. We believe Dr. Dybul’s extensive high-level clinical and institutional experience in the field of HIV/AIDS qualifies him to serve as a director.

Luisa Puche

Chief Financial Officer


Luisa Puche, has served as a senior accounting and financial advisor and president of Puche Group, LLC, since 2015. She has served in a variety of advisory capacities for both public and private organizations, such as technical accounting consultations; complex technical implementations, M&A transactions; IT Risk assessments; and SOX 404 implementations. Leveraging her broad global audit, advisory, and corporate expertise, Luisa has provided strong cross-functional leadership experience managing small and large projects for both publicly-traded and privately-held companies in various industries including a global implementation of the latest revenue recognition accounting standard for Del Monte, a $4B publicly traded global fresh produce company, as well as the global implementation of their SOX-404 program.

Previously, Luisa served in various senior executive roles at Brightstar Corp., a $10B global wireless device services provider, with public reporting requirements, including as Vice President and Global Controller and Interim Chief Accounting Officer. During her tenure at the Company she was responsible for the financial reporting of 55 countries, as well as instrumental in various key transactions including an $1.6B European acquisition and the sale of Brightstar to SoftBank. Luisa was also an executive at Ernst & Young, a big 4 accounting firm, where she worked for 10 years.

Highlights of her public company clients include: Del Monte Fresh Produce Company, Royal Palm Venture Capital, Terremark Worldwide, Knight-Ridder, Inc. and Vanguard Car Rental, Inc. (formerly Alamo and National Car Rental).
Luisa holds a Bachelor’s of Accounting from Florida International University. The above qualifies Luisa Puche to serve as CFO.

Dr. Serhat Gümrükcü



Dr. Serhat Gümrükcü has been at the forefront of cell, gene and immunotherapy for more than a decade. After his medical training at Dokuz Eylul University (2004) and Istanbul Marmara University (2006), he continued his clinical training and practice in different centers around Europe including University of Edinburgh United Kingdom, Pierre & Marie Curie University Saint Antoine Teaching Hospital, France and Institute of Bioregulation St Petersburg, Russia.

His interest in other fields of science, like physics, has led him to pursue creating cross-disciplinary solutions to complex human diseases as a researcher of his own clinical work and as a consulting diagnostician and clinician for heads of states, prominent families and world leaders. Besides his professional work in the field, he has spent significant amount of time providing medical care to underserved communities in Africa, Asia and the Middle East. Dr. Gümrükçü’s innovative research has focused on cancer immunotherapy, stem cell and transplant biology, and regenerative medicine. His main objective is to develop better stem cell transplant, and cell and gene therapy treatments for patients with cancer, rare genetic disorders, and infectious diseases.

Based on his unique research training, Dr. Gümrükcü has become a prolific inventor, submitting various patents including for several approaches to cure HIV/AIDS, Hepatitis B, major solid tumors, rare but deadly diseases, and for a novel vaccine for HIV among many others.

Dr. Gümrükcü has licensed all intellectual property related to HIV and several solid tumors to Enochian Biosciences, where he serves as Senior Scientific Advisor. He is the director of Seraph Research Institute, a non-profit organization where he also runs his research lab at the cutting edge of cell, gene and immunotherapy.

Dr. Gümrükcü is a member of American Society of Clinical Oncology (ASCO), International AIDS Society (IAS), HIV Medicine Association (HIVMA), and American Society of Gene & Cell Therapy (ASGCT) where he was appointed to serve on the Cancer Cell & Gene Therapy Committee and Infectious Diseases and Vaccines Committee in recognition of his “leadership in the field”.

Christine Mikail

Strategic Advisor & Chair, IP Committee


Christine Mikail has spent nearly two decades in the biopharma industry serving in a variety of roles spanning corporate strategy and business development, managing and building operations at start-up companies and constructing and executing on complex financings and life sciences transactions. Most recently, as a strategic advisor to start up and mid-size biotech companies, she recently helped co-found two emerging growth companies. In those companies, Christine helped shape the financing strategy and completed several key business development deals.

Previously, Christine served as CAO, head of external business development and general counsel of Axovant Sciences where she was part of the small leadership team of five that took Axovant public in 2015 with a $362 million IPO, the largest biotech IPO in history at the time. Christine built operations from the ground up and led business development at this fast-growing company. Prior to that, she was senior vice president for legal affairs, general counsel and board secretary at NPS Pharmaceuticals, Inc., where she was an integral part of its sale to Shire Pharmaceuticals for $5.2 billion. Christine also was executive vice president for corporate development at the Dendreon Corporation, where she led the company’s restructurings that culminated in its sale to Valeant. She also held several roles at ImClone Systems and Eli Lilly, including an instrumental role in the sale of ImClone to Lilly for $6.5 billion.

She received her bachelor’s degree from Rutgers University and her JD from Fordham University School of Law.

Dr. Wenshi Wang

SVP Operations


Dr. Wang has been actively overseeing, working and completing Investigation New Drug (IND) filing with FDA on stem cell and T cell therapy demonstrating her leadership in drug discovery and development. Dr. Wang completed her clinical medicine and her Immunology PhD training in China and at Heidelberg University in Germany. In the United States, Dr. Wang advanced her career in translational immune-oncology at the University of Southern California and Moffitt Cancer Center in Florida with achievements in patent issuance and publications in the industry’s top peer-reviewed journals.

Tung Nguyen

Senior Molecular Biologist


Devoting more than a quarter of a century on research with focus on signal transduction and molecular basic of cancer and infection, Tung is eager to transform his passion for Science into cures for diseases, to fulfill his life-long wish on helping people and saving lives.

He conducted research at the Molecular Oncology Department at John Wayne Cancer Institute, the Molecular Host Defense Laboratory at UCLA and the Molecular Immunology at Beckman Research Institute at City of Hope Medical Center. And “this is exactly where I want to be today …”, he stated upon joining Enochian Biosciences team.